Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
about
Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala studyGlatiramer acetate: long-term safety and efficacy in relapsing-remitting multiple sclerosis.Cost-Effectiveness Modeling in Multiple Sclerosis: Playing Around with Non-Healthcare Costs?Estimate of the cost of multiple sclerosis in Spain by literature review.Disease-Modifying Therapies for Multiple Sclerosis: A Systematic Literature Review of Cost-Effectiveness Studies.
P2860
Cost-effectiveness of glatiramer acetate and interferon beta-1a for relapsing-remitting multiple sclerosis, based on the CombiRx study.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Cost-effectiveness of glatiram ...... s, based on the CombiRx study.
@en
Cost-effectiveness of glatiram ...... s, based on the CombiRx study.
@nl
type
label
Cost-effectiveness of glatiram ...... s, based on the CombiRx study.
@en
Cost-effectiveness of glatiram ...... s, based on the CombiRx study.
@nl
prefLabel
Cost-effectiveness of glatiram ...... s, based on the CombiRx study.
@en
Cost-effectiveness of glatiram ...... s, based on the CombiRx study.
@nl
P2093
P1476
Cost-effectiveness of glatiram ...... s, based on the CombiRx study.
@en
P2093
Josep Darbà
Lisette Kaskens
Rainel Sánchez-de la Rosa
P304
P356
10.3111/13696998.2014.890936
P407
P577
2014-03-01T00:00:00Z